Limits...
EBV-Associated Cancer and Autoimmunity: Searching for Therapies.

Capone G, Fasano C, Lucchese G, CalabrĂ² M, Kanduc D - Vaccines (Basel) (2015)

Bottom Line: Epstein-Barr virus (EBV) infects B-, T-, and NK cells and has been associated not only with a wide range of lymphoid malignancies but also with autoimmune diseases such as lupus erythematosus, rheumatoid arthritis and, in particular, multiple sclerosis.Hence, effective immunotherapeutic approaches to eradicate EBV infection might overthrow cancer and autoimmunity incidence.Here we use the concept that protein immunogenicity is allocated in rare peptide sequences and search the Epstein-Barr nuclear antigen 1 (EBNA1) sequence for peptides unique to the viral protein and absent in the human host.

View Article: PubMed Central - PubMed

Affiliation: Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari 70126, Italy. g.capone@biologia.uniba.it.

ABSTRACT
Epstein-Barr virus (EBV) infects B-, T-, and NK cells and has been associated not only with a wide range of lymphoid malignancies but also with autoimmune diseases such as lupus erythematosus, rheumatoid arthritis and, in particular, multiple sclerosis. Hence, effective immunotherapeutic approaches to eradicate EBV infection might overthrow cancer and autoimmunity incidence. However, currently no effective anti-EBV immunotherapy is available. Here we use the concept that protein immunogenicity is allocated in rare peptide sequences and search the Epstein-Barr nuclear antigen 1 (EBNA1) sequence for peptides unique to the viral protein and absent in the human host. We report on a set of unique EBV EBNA1 peptides that might be used in designing peptide-based therapies able to specifically hitting the virus or neutralizing pathogenic autoantibodies.

No MeSH data available.


Related in: MedlinePlus

Pentapeptide identity platform shared between EBV GP350 protein and the human proteome. Peptide aa sequences in one letter code.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4494242&req=5

vaccines-03-00074-f002: Pentapeptide identity platform shared between EBV GP350 protein and the human proteome. Peptide aa sequences in one letter code.

Mentions: The present study proposes the principle of peptide uniqueness [22,23,24,25] to construct and develop specific and efficacious EBV vaccines that are exempt from potential crossreactions. In this regard, our findings might also help avoid potential crossreactions in EBV GP350 antigen-based vaccine currently under trial to prevent infectious mononucleosis [83,84]. As a matter of fact, the pentapeptide identity platform shared by EBV GP350 antigen and the human proteome (Appendix Figure A1) reproposes a relevant pentapeptide overlap between EBV GP350 and human proteins, in analogy to the results obtained for EBV EBNA1 and illustrated in Figure 1.


EBV-Associated Cancer and Autoimmunity: Searching for Therapies.

Capone G, Fasano C, Lucchese G, CalabrĂ² M, Kanduc D - Vaccines (Basel) (2015)

Pentapeptide identity platform shared between EBV GP350 protein and the human proteome. Peptide aa sequences in one letter code.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4494242&req=5

vaccines-03-00074-f002: Pentapeptide identity platform shared between EBV GP350 protein and the human proteome. Peptide aa sequences in one letter code.
Mentions: The present study proposes the principle of peptide uniqueness [22,23,24,25] to construct and develop specific and efficacious EBV vaccines that are exempt from potential crossreactions. In this regard, our findings might also help avoid potential crossreactions in EBV GP350 antigen-based vaccine currently under trial to prevent infectious mononucleosis [83,84]. As a matter of fact, the pentapeptide identity platform shared by EBV GP350 antigen and the human proteome (Appendix Figure A1) reproposes a relevant pentapeptide overlap between EBV GP350 and human proteins, in analogy to the results obtained for EBV EBNA1 and illustrated in Figure 1.

Bottom Line: Epstein-Barr virus (EBV) infects B-, T-, and NK cells and has been associated not only with a wide range of lymphoid malignancies but also with autoimmune diseases such as lupus erythematosus, rheumatoid arthritis and, in particular, multiple sclerosis.Hence, effective immunotherapeutic approaches to eradicate EBV infection might overthrow cancer and autoimmunity incidence.Here we use the concept that protein immunogenicity is allocated in rare peptide sequences and search the Epstein-Barr nuclear antigen 1 (EBNA1) sequence for peptides unique to the viral protein and absent in the human host.

View Article: PubMed Central - PubMed

Affiliation: Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Bari 70126, Italy. g.capone@biologia.uniba.it.

ABSTRACT
Epstein-Barr virus (EBV) infects B-, T-, and NK cells and has been associated not only with a wide range of lymphoid malignancies but also with autoimmune diseases such as lupus erythematosus, rheumatoid arthritis and, in particular, multiple sclerosis. Hence, effective immunotherapeutic approaches to eradicate EBV infection might overthrow cancer and autoimmunity incidence. However, currently no effective anti-EBV immunotherapy is available. Here we use the concept that protein immunogenicity is allocated in rare peptide sequences and search the Epstein-Barr nuclear antigen 1 (EBNA1) sequence for peptides unique to the viral protein and absent in the human host. We report on a set of unique EBV EBNA1 peptides that might be used in designing peptide-based therapies able to specifically hitting the virus or neutralizing pathogenic autoantibodies.

No MeSH data available.


Related in: MedlinePlus